Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(3-4):433–439. doi: 10.1038/sj.bjc.6690067

In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats

A H van der Veen 1, A L B Seynhaeve 1, J Breurs 1, P T G A Nooijen 2, R L Marquet 1, A M M Eggermont 1
PMCID: PMC2362422  PMID: 10027309

Abstract

Isolated perfusion of the extremities with high-dose tumour necrosis factor α (TNF-α) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-α and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 μg TNF-α. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-α and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-α alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-α, the minimal threshold concentration of TNF-α to exert its anti-tumour effects was not reached. The applicability of TNF-α in isolated kidney perfusion for human tumours seems, therefore, questionable. © 1999 Cancer Research Campaign

Keywords: tumour necrosis factor α, isolated kidney perfusion, rats

Full Text

The Full Text of this article is available as a PDF (169.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Affres H., Perez J., Hagege J., Fouqueray B., Kornprobst M., Ardaillou R., Baud L. Desferrioxamine regulates tumor necrosis factor release in mesangial cells. Kidney Int. 1991 May;39(5):822–830. doi: 10.1038/ki.1991.103. [DOI] [PubMed] [Google Scholar]
  2. Asbach H. W., Bersch W. The effect of in situ isolated perfusion of experimental renal tumors with cytotoxic agents in high concentration. Urol Int. 1980;35(2):112–124. doi: 10.1159/000280311. [DOI] [PubMed] [Google Scholar]
  3. Asher A., Mulé J. J., Reichert C. M., Shiloni E., Rosenberg S. A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987 Feb 1;138(3):963–974. [PubMed] [Google Scholar]
  4. Baud L., Ardaillou R. Tumor necrosis factor in renal injury. Miner Electrolyte Metab. 1995;21(4-5):336–341. [PubMed] [Google Scholar]
  5. Borel Rinkes I. H., de Vries M. R., Jonker A. M., Swaak T. J., Hack C. E., Nooyen P. T., Wiggers T., Eggermont A. M. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br J Cancer. 1997;75(10):1447–1453. doi: 10.1038/bjc.1997.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brouckaert P. G., Leroux-Roels G. G., Guisez Y., Tavernier J., Fiers W. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer. 1986 Nov 15;38(5):763–769. doi: 10.1002/ijc.2910380521. [DOI] [PubMed] [Google Scholar]
  7. Dealtry G. B., Naylor M. S., Fiers W., Balkwill F. R. The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells. Exp Cell Res. 1987 Jun;170(2):428–438. doi: 10.1016/0014-4827(87)90318-1. [DOI] [PubMed] [Google Scholar]
  8. Eggermont A. M., Schraffordt Koops H., Klausner J. M., Kroon B. B., Schlag P. M., Liénard D., van Geel A. N., Hoekstra H. J., Meller I., Nieweg O. E. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996 Dec;224(6):756–765. doi: 10.1097/00000658-199612000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Eggermont A. M., Schraffordt Koops H., Liénard D., Kroon B. B., van Geel A. N., Hoekstra H. J., Lejeune F. J. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996 Oct;14(10):2653–2665. doi: 10.1200/JCO.1996.14.10.2653. [DOI] [PubMed] [Google Scholar]
  10. Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D., Allison A. C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992 Mar;140(3):539–544. [PMC free article] [PubMed] [Google Scholar]
  11. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S., Gutterman J. U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988 Aug;6(8):1328–1334. doi: 10.1200/JCO.1988.6.8.1328. [DOI] [PubMed] [Google Scholar]
  12. Fine L. The biology of renal hypertrophy. Kidney Int. 1986 Mar;29(3):619–634. doi: 10.1038/ki.1986.45. [DOI] [PubMed] [Google Scholar]
  13. Gaskill H. V., 3rd Continuous infusion of tumor necrosis factor: mechanisms of toxicity in the rat. J Surg Res. 1988 Jun;44(6):664–671. doi: 10.1016/0022-4804(88)90098-4. [DOI] [PubMed] [Google Scholar]
  14. Hieber U., Heim M. E. Tumor necrosis factor for the treatment of malignancies. Oncology. 1994 Mar-Apr;51(2):142–153. doi: 10.1159/000227329. [DOI] [PubMed] [Google Scholar]
  15. Kahky M. P., Daniel C. O., Cruz A. B., Gaskill H. V., 3rd Portal infusion of tumor necrosis factor increases mortality in rats. J Surg Res. 1990 Aug;49(2):138–145. doi: 10.1016/0022-4804(90)90252-w. [DOI] [PubMed] [Google Scholar]
  16. Kallinowski F., Schaefer C., Tyler G., Vaupel P. In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer. 1989 Oct;60(4):555–560. doi: 10.1038/bjc.1989.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kramer S. M., Carver M. E. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods. 1986 Nov 6;93(2):201–206. doi: 10.1016/0022-1759(86)90189-4. [DOI] [PubMed] [Google Scholar]
  18. Lejeune F. J., Liénard D., Leyvraz S., Mirimanoff R. O. Regional therapy of melanoma. Eur J Cancer. 1993;29A(4):606–612. doi: 10.1016/s0959-8049(05)80163-7. [DOI] [PubMed] [Google Scholar]
  19. Maessen J. G., Greve J. W., Buurman W. A. Increased sensitivity to endotoxemia by tissue necrosis. Surgery. 1991 Feb;109(2):154–159. [PubMed] [Google Scholar]
  20. Manusama E. R., Nooijen P. T., Stavast J., Durante N. M., Marquet R. L., Eggermont A. M. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996 Apr;83(4):551–555. doi: 10.1002/bjs.1800830438. [DOI] [PubMed] [Google Scholar]
  21. Manusama E. R., Stavast J., Durante N. M., Marquet R. L., Eggermont A. M. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol. 1996 Apr;22(2):152–157. doi: 10.1016/s0748-7983(96)90671-x. [DOI] [PubMed] [Google Scholar]
  22. Marquet R. L., Westbroek D. L., Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer. 1984 May 15;33(5):689–692. doi: 10.1002/ijc.2910330521. [DOI] [PubMed] [Google Scholar]
  23. Nooijen P. T., Manusama E. R., Eggermont A. M., Schalkwijk L., Stavast J., Marquet R. L., de Waal R. M., Ruiter D. J. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer. 1996 Dec;74(12):1908–1915. doi: 10.1038/bjc.1996.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
  25. Pass H. I., Mew D. J., Kranda K. C., Temeck B. K., Donington J. S., Rosenberg S. A. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg. 1996 Jun;61(6):1609–1617. doi: 10.1016/0003-4975(96)00166-X. [DOI] [PubMed] [Google Scholar]
  26. Pogrebniak H. W., Witt C. J., Terrill R., Kranda K., Travis W. D., Rosenberg S. A., Pass H. I. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg. 1994 Jun;57(6):1477–1483. doi: 10.1016/0003-4975(94)90104-x. [DOI] [PubMed] [Google Scholar]
  27. Shimomura K., Manda T., Mukumoto S., Kobayashi K., Nakano K., Mori J. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer. 1988 Feb 15;41(2):243–247. doi: 10.1002/ijc.2910410215. [DOI] [PubMed] [Google Scholar]
  28. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  29. Tipping P. G., Leong T. W., Holdsworth S. R. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest. 1991 Sep;65(3):272–279. [PubMed] [Google Scholar]
  30. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  31. Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988 Apr 15;48(8):2179–2183. [PubMed] [Google Scholar]
  32. Weksler B., Blumberg D., Lenert J. T., Ng B., Fong Y., Burt M. E. Isolated single-lung perfusion with TNF-alpha in a rat sarcoma lung metastases model. Ann Thorac Surg. 1994 Aug;58(2):328–332. doi: 10.1016/0003-4975(94)92202-0. [DOI] [PubMed] [Google Scholar]
  33. Weksler B., Schneider A., Ng B., Burt M. Isolated single lung perfusion in the rat: an experimental model. J Appl Physiol (1985) 1993 Jun;74(6):2736–2739. doi: 10.1152/jappl.1993.74.6.2736. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES